GlaxoSmithkline Pharmaceuticals Ltd.

BSE: GLAXO500660ISIN INE159A01016

Healthcare
Pharmaceuticals
BSE 200

BSE listing

Share price

₹2,851.85+51.40 (+1.84%)

as of 18 Sep 2026

52W high: ₹3,121.10
52W low: ₹2,088.00
Off 52W high: -8.63%
1M return: -6.01%
3M return: +22.25%
6M return: +19.78%
1Y return: +3.73%
20D avg volume: 19,352
50 DMA: ₹2,737.96
200 DMA: ₹2,498.42

Key ratios Consolidated

Market cap: ₹48,312 Cr
Current price: ₹2,851.85
52W high / low: ₹3,121.10 / ₹2,088.00
Face value: ₹10.00
P/E: 45.23
P/B: —
EPS (TTM): ₹63.05
Book value / share: —
ROE: —
ROCE: 55.40%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-1,102 Cr
Interest cover: 516.02
Dividend yield: 2.00%
Dividend / share (TTM): ₹57.00
Payout: 90.40%
Cash conversion cycle: 15.3 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	938.44	995.30	1,041	979.94	805.17	974.37	949.42	1,011	814.65	929.80	805.26	956.99
	43.76	35.95	32.12	33.57	43.72	40.68	35.07	34.54	35.64	29.83	28.11	28.21
	659.75	658.15	691.43	662.15	569.91	656.48	676.39	706.19	600.89	691.41	604.63	686.04
	72.95	113.06	79.90	115.13	128.06	115.23	97.48	148.96	138.23	204.60	90.95	91.21
	378.62	228.40	217.27	232.72	232.06	291.40	164.23	216.74	172.74	255.74	162.52	260.62
	159.04	164.75	151.88	138.05	152.57	152.97	124.74	150.71	151.28	172.83	141.35	145.21
	0.97	0.61	1.19	0.51	0.42	0.58	0.09	0.27	0.37	0.77	0.32	0.43
	15.84	13.17	20.32	17.43	15.52	14.72	18.80	16.86	16.41	18.10	17.11	18.11
	155.96	135.62	154.22	150.63	113.69	136.27	173.60	153.86	137.56	132.58	129.01	167.85
	322.45	373.10	381.95	351.36	278.98	358.57	308.10	339.12	249.40	268.22	228.74	299.16
	0.00	0.00	17.98	2.64	0.00	0.00	0.00	4.69	0.00	2.40	-163.31	0.00
	322.45	373.10	399.93	354.00	278.98	358.57	308.10	343.81	249.40	270.62	65.43	299.16
	85.27	95.24	104.31	96.51	73.97	95.70	78.22	91.31	67.07	76.14	19.71	81.65
	237.18	277.86	295.62	257.49	205.01	262.87	229.88	252.50	182.33	194.48	45.72	217.51
	14.00	16.40	16.54	15.07	12.10	15.52	13.57	14.67	10.76	11.48	9.89	12.84
Key metrics
	339.26	386.88	421.44	371.94	294.92	373.87	326.99	360.94	266.18	289.49	82.86	317.70
	36.20%	38.90%	40.50%	38.00%	36.60%	38.40%	34.40%	35.70%	32.70%	31.10%	10.30%	33.20%
	25.30%	27.90%	28.40%	26.30%	25.50%	27.00%	24.20%	25.00%	22.40%	20.90%	5.70%	22.70%
	—	14.70%	—	17.80%	—	16.30%	—	—	—	—	—	—
	16.60%	2.10%	9.70%	-3.10%	-1.20%	4.80%	17.90%	5.60%	—	—	—	—
	15.70%	5.70%	28.60%	2.00%	12.40%	35.20%	402.80%	16.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	3,955	3,822	3,749	3,454	3,252	3,278	3,199	3,224	3,128	2,896
	145.40	145.36	145.93	122.59	100.66	75.78	110.58	79.01	102.32	54.54
	2,671	2,582	2,640	2,616	2,515	2,586	2,586	2,656	2,576	2,428
	381.04	436.15	499.90	545.17	427.48	611.18	472.02	474.38	686.57	510.82
	1,057	910.45	845.11	853.08	788.43	729.44	880.11	868.92	645.89	788.42
	613.72	607.25	579.70	624.39	594.99	610.23	614.69	628.55	537.20	523.40
	3.28	2.73	1.31	1.80	1.81	2.00	3.53	6.34	0.55	0.19
	66.76	66.44	66.79	69.68	65.77	68.19	79.28	82.68	48.59	—
	596.43	554.16	601.29	586.10	567.57	549.73	576.14	630.71	632.10	600.94
	1,429	1,385	1,255	959.80	837.37	767.47	723.10	647.24	653.97	522.17
	20.62	20.62	4.69	-143.61	-0.97	11.58	-172.60	-341.49	28.69	17.80
	1,449	1,406	1,260	816.19	836.40	779.05	550.50	305.75	682.66	539.97
	381.33	370.03	332.30	226.23	228.76	398.28	192.35	212.55	237.27	189.25
	1,068	1,036	927.58	589.96	610.69	1,695	358.15	93.20	445.39	350.72
	62.01	54.52	54.52	34.83	35.87	22.48	21.14	5.50	26.29	—
Key metrics
	1,520	1,475	1,328	887.67	903.98	849.24	633.31	394.77	731.80	540.16
	38.42%	38.60%	35.40%	25.70%	27.80%	25.90%	19.80%	12.20%	23.40%	18.70%
	27.01%	27.10%	24.70%	17.10%	18.80%	51.70%	11.20%	2.90%	14.20%	12.10%
	—	55.40%	57.30%	—	—	—	—	—	—	—
	—	1.90%	8.60%	6.20%	-0.80%	2.50%	-0.80%	3.10%	8.00%	—
	—	11.70%	57.20%	-3.40%	-64.00%	373.20%	284.30%	-79.10%	27.00%	—
	—	848.02	1,267	—	—	—	—	—	—	—
	—	0.87	1.39	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	-1,102	-538.85	—	—	—	—	—	—	—
	—	15.3	6.4	—	—	—	—	—	—	—
Balance sheet
	—	4,324	4,108	—	—	—	—	—	—	—
	—	3,785	3,606	—	—	—	—	—	—	—
	—	1,102	538.85	—	—	—	—	—	—	—
	—	273.11	292.55	—	—	—	—	—	—	—
	—	457.55	481.74	—	—	—	—	—	—	—
	—	54.38	43.05	—	—	—	—	—	—	—
	—	273.51	269.54	—	—	—	—	—	—	—
	—	570.22	708.26	—	—	—	—	—	—	—
	—	1,779	1,905	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	2,285	1,951	—	—	—	—	—	—	—
Cash flow
	—	903.30	1,290	—	—	—	—	—	—	—
	—	396.98	-45.81	—	—	—	—	—	—	—
	—	-737.08	-769.42	—	—	—	—	—	—	—
	—	55.28	23.02	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	924.42	989.15	1,023	973.63	804.83	966.08	946.36	1,000	811.00	910.87	804.98	953.38
	61.63	35.71	31.82	31.27	43.76	39.46	35.06	32.19	35.85	29.87	28.34	28.47
	648.07	655.74	676.52	656.89	570.02	650.64	675.07	698.23	598.36	674.43	604.90	685.34
	59.87	101.47	70.10	107.07	121.43	108.35	91.93	137.25	133.33	192.29	87.52	79.71
	378.62	228.39	217.27	232.71	232.07	291.40	164.23	216.74	172.74	255.74	162.52	260.62
	159.04	164.75	151.88	138.05	152.57	152.97	124.74	150.71	151.28	172.83	141.35	145.21
	0.97	0.61	1.19	0.51	0.42	0.58	0.09	0.27	0.37	0.77	0.32	0.43
	15.84	13.17	20.32	17.43	15.52	14.72	18.80	16.86	16.41	18.10	17.11	18.11
	155.77	140.79	154.05	150.36	113.54	136.03	180.00	153.78	137.49	133.60	132.15	171.55
	337.98	369.12	377.89	348.01	278.57	354.90	306.35	334.01	248.49	266.31	228.42	296.51
	0.00	0.00	0.00	2.64	0.00	0.00	—	4.69	—	2.40	-163.31	—
	337.98	369.12	377.89	350.65	278.57	354.90	306.35	338.70	248.49	268.71	65.11	296.51
	84.65	94.18	100.71	95.65	73.87	94.76	77.77	90.01	66.84	75.63	19.62	80.97
	253.33	274.94	277.18	255.00	204.70	260.14	228.58	248.69	181.65	193.08	45.49	215.54
	14.95	16.23	16.36	14.92	12.08	15.35	13.49	14.45	10.72	11.39	9.88	12.72
Key metrics
	354.79	382.90	399.40	368.59	294.51	370.20	325.24	355.83	265.27	287.58	82.54	315.05
	38.40%	38.70%	39.10%	37.90%	36.60%	38.30%	34.40%	35.60%	32.70%	31.60%	10.30%	33.00%
	27.40%	27.80%	27.10%	26.20%	25.40%	26.90%	24.20%	24.90%	22.40%	21.20%	5.70%	22.60%
	—	14.70%	—	17.70%	—	16.20%	—	—	—	—	—	—
	14.90%	2.40%	8.10%	-2.60%	-0.80%	6.10%	17.60%	4.90%	—	—	—	—
	23.80%	5.70%	21.30%	2.50%	12.70%	34.70%	402.50%	15.40%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	3,910	3,790	3,723	3,407	3,216	3,218	3,194	3,225	3,129	2,896
	160.43	142.56	142.56	123.48	101.52	76.22	110.19	77.56	101.48	53.52
	2,637	2,559	2,622	2,578	2,485	2,532	2,582	2,655	2,571	2,426
	338.51	400.07	470.86	504.99	394.35	552.47	452.64	474.38	682.07	510.27
	1,057	910.44	845.11	853.08	788.43	729.44	880.11	868.92	645.89	788.42
	613.72	607.25	579.70	624.39	594.99	610.23	614.69	628.55	537.20	523.40
	3.28	2.73	1.31	1.80	1.81	1.99	3.53	6.34	0.55	0.19
	66.76	66.44	66.79	69.68	65.77	68.19	79.28	82.68	48.59	37.99
	600.97	558.74	607.30	593.78	571.91	555.71	578.87	629.81	631.32	599.10
	1,433	1,374	1,244	952.65	833.35	761.87	722.33	646.99	658.82	523.78
	2.64	2.64	4.69	-143.61	-0.97	11.58	-172.60	-324.49	4.89	17.80
	1,436	1,376	1,248	809.04	832.38	773.45	549.73	322.50	663.71	541.58
	375.19	364.41	329.38	224.35	227.68	396.87	192.17	212.45	238.35	189.60
	1,060	1,012	919.06	584.69	607.75	1,691	357.56	110.05	425.36	351.98
	62.46	59.00	54.01	34.51	35.70	22.23	21.11	6.50	25.11	—
Key metrics
	1,506	1,445	1,317	880.52	899.96	843.63	632.54	411.52	712.85	579.76
	38.51%	38.10%	35.40%	25.80%	28.00%	26.20%	19.80%	12.80%	22.80%	20.00%
	27.12%	26.70%	24.70%	17.20%	18.90%	52.50%	11.20%	3.40%	13.60%	12.20%
	—	54.80%	56.80%	—	—	—	—	—	—	—
	—	1.80%	9.30%	5.90%	0.00%	0.70%	-1.00%	3.10%	8.00%	—
	—	10.10%	57.20%	-3.80%	-64.00%	372.80%	224.90%	-74.10%	20.80%	—
	—	826.14	1,257	—	—	—	—	—	—	—
	—	0.87	1.39	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	-1,066	-536.22	—	—	—	—	—	—	—
	—	14.8	5.1	—	—	—	—	—	—	—
Balance sheet
	—	4,275	4,101	—	—	—	—	—	—	—
	—	3,722	3,576	—	—	—	—	—	—	—
	—	1,066	536.22	—	—	—	—	—	—	—
	—	273.11	292.55	—	—	—	—	—	—	—
	—	430.35	463.17	—	—	—	—	—	—	—
	—	54.40	43.05	—	—	—	—	—	—	—
	—	273.51	269.54	—	—	—	—	—	—	—
	—	549.65	704.00	—	—	—	—	—	—	—
	—	1,757	1,901	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	2,241	1,949	—	—	—	—	—	—	—
Cash flow
	—	881.42	1,280	—	—	—	—	—	—	—
	—	385.25	-36.54	—	—	—	—	—	—	—
	—	-737.07	-769.42	—	—	—	—	—	—	—
	—	55.28	23.02	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +5.62%
Sales CAGR 5Y: +3.48%
Sales CAGR 10Y: —
Profit CAGR 3Y: +18.52%
Profit CAGR 5Y: +23.13%
Profit CAGR 10Y: —
Sales YoY (TTM): +5.18%
Profit YoY (TTM): +12.56%

Consolidated

Sales CAGR 3Y: +5.53%
Sales CAGR 5Y: +3.62%
Sales CAGR 10Y: —
Profit CAGR 3Y: +19.26%
Profit CAGR 5Y: +23.67%
Profit CAGR 10Y: —
Sales YoY (TTM): +5.75%
Profit YoY (TTM): +12.41%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 75.00%

Holder	Type	Holding	Previous	Change
GLAXO GROUP LIMITED	Promoter	35.99%	—	—
GLAXOSMITHKLINE PTE LIMITED	Promoter Group	28.10%	—	—
ESKAYLAB LIMITED	Promoter Group	6.94%	—	—
BURROUGHS WELLCOME INTERNATIONAL LIMITED	Promoter Group	3.97%	—	—
LICI ASM NON PAR	Public	1.08%	—	—
FOREIGN BANK	Public	0.00%	—	—
FOREIGN INSTITUTIONAL INVESTORS	Public	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

As per attachment15 Sep 2026 · AGM/EGM / Postal Ballot
Outcome of Postal Ballot15 Sep 2026 · AGM/EGM / Postal Ballot
As per attachment2 Sep 2026 · Company Update / Newspaper Publication
As per attachment1 Sep 2026 · AGM/EGM / Postal Ballot
As per attachment26 Aug 2026 · Company Update / General
The Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Ltd on August 26, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.26 Aug 2026 · Company Update / Clarification
As per attachment19 Aug 2026 · Company Update / General
As per attachment14 Aug 2026 · Company Update / Newspaper Publication
As per attachment13 Aug 2026 · AGM/EGM / Postal Ballot
Transcript6 Aug 2026 · Company Update / Analyst / Investor Meet
IT Refund of Rs 52 crores6 Aug 2026 · Company Update / General
As per attachment5 Aug 2026 · Company Update / Analyst / Investor Meet
As per attachment4 Aug 2026 · Company Update / Newspaper Publication
As per attachment3 Aug 2026 · Company Update / Analyst / Investor Meet
Reappointment of Managing Director3 Aug 2026 · Company Update / Change in Management
As per attachment3 Aug 2026 · Company Update / Resignation of Director
As per attachment3 Aug 2026 · Company Update / Change in Directorate
As per attachment3 Aug 2026 · Company Update / Press Release / Media Release
Presentation3 Aug 2026 · Company Update / Analyst / Investor Meet
Outcome of meeting3 Aug 2026 · Result / Financial Results
Outcome of Meeting3 Aug 2026 · Board Meeting / Outcome of Board Meeting
As per attachment21 Jul 2026 · Company Update / Analyst / Investor Meet
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 ,inter alia, to consider and approve approve and ....21 Jul 2026 · Board Meeting / Board Meeting
As per attachment8 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per attachment30 Jun 2026 · AGM/EGM / AGM
As per attachment30 Jun 2026 · AGM/EGM / AGM
As per attachment26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
As per attachment25 Jun 2026 · Company Update / General
As per attachment9 Jun 2026 · Company Update / Newspaper Publication
As per attachment8 Jun 2026 · Company Update / General
As per attachment5 Jun 2026 · AGM/EGM / AGM
BRSR Report for 2025-265 Jun 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for 2025-265 Jun 2026 · Others / Reg. 34 (1) Annual Report
As per attachment2 Jun 2026 · Company Update / Newspaper Publication
As per attachment29 May 2026 · Company Update / Newspaper Publication
Resignation of Dr. Simrat Sohal as Compliance officer of the Company29 May 2026 · Company Update / Change in Management
Annual Compliance Secretarial Report for year ended March 202626 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
As per attachment18 May 2026 · Company Update / Analyst / Investor Meet
As per attachment14 May 2026 · Company Update / Newspaper Publication
As per attachment13 May 2026 · Company Update / Analyst / Investor Meet

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 57.0000	29 May 2026	29 May 2026	—
Final Dividend - Rs. - 42.0000	30 May 2025	30 May 2025	—
Interim Dividend - Rs. - 12.0000	7 Nov 2024	7 Nov 2024	—

Board meetings

3 Aug 2026 Board Meeting - Financial Results